excelra

GOBIOM Use Case 2

Identification of efficacy, response to therapy and drug resistance biomarkers in breast cancer

- ✓ A drug development team in a big pharmaceutical company working on BCL-2 inhibitors is keen on identifying biomarkers of efficacy, response to therapy and drug resistance in breast cancer
- ✓ Once the efficacy biomarkers have been identified the group intends to design effective clinical trials to study the effectiveness of the drug
- ✓ Also, identification of response to therapy and resistance biomarkers will aid in identifying right study population for clinical trials

✓ A search in GOBIOM database by keyword ‘BCL-2’ in ‘Target Name’, keyword “Efficacy” in ‘Application’ and ‘Breast cancer’ in ‘Indication’ retrieves all the efficacy biomarkers reported in breast cancer



Home / Search / Advanced Search Result

Hide Filters

Applied Filters Collapse All

- Biomarker
- Indication
- Application
- Drugs
- Phenotypes
- Clinical Trials
- Pathways
- Gene Ontology
- Year of Publication



Selected Fields: diseasename : Breast Cancer, Application : Efficacy, drugtarget : Apoptosis regulator Bcl-2
Attributes Fields:

Show/Hide attributes | Save Query

Number of Records : 273

10 Show entries

Search:

Previous 1 2 3 4 5 ... 28 Next

Watch	Visualization	EBMID	Biomarker Name	Disease Name	Biomarker Type	Biomarker Class	Biomarker Status	Approval Status	Applications	Drugs	No of Clinical Trials	No of References
		ONC-34937	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Drug Resistance, Response To Therapy, (more...)	BIBW 2992, VORINOSTAT, PEGFILGRASTIM, (more...)	63	380
		ONC-15931	ESTROGEN RECEPTOR	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Drug Resistance, Response To Therapy, (more...)	ADRIAMYCIN, CYTOXAN, FLUVASTATIN SODIU(more...)	51	155
		ONC-37936	PROGESTERONE RECEPTOR	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Prognosis, Diagnosis, Response To Ther(more...)	MIFEPRISTONE, GEMCITABINE, FULVESTRANT(more...)	31	116

Identification of qualified and most relevant efficacy biomarkers would aid the group in

- ✓ Designing effective clinical trials
- ✓ Reduce biomarker discovery costs
- ✓ Make informed decisions i.e. crucial Go/no go decisions in drug development
- ✓ Designing later-phase clinical studies

A similar search in GOBIOM database by keyword ‘BCL-2’ in ‘Target Name’, keywords “Response to therapy” “Drug resistance” in ‘Application’ and ‘Breast cancer’ in ‘Indication’ retrieves all the drug response biomarkers reported in breast cancer





Identification of qualified and most relevant drug response biomarkers would aid the group in

- ✓ Stratification of patients who are most likely to respond to treatment
- ✓ Designing tailor made treatment regimens based on their predicted response
- ✓ Segregating patients with resistance phenotypes into focused treatment groups



www.excelra.com

THANK YOU

excelra